Anbio Biotechnology Class A Ordinary Shares (NNNN) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

Anbio Biotechnology Class A Ordinary Shares (NNNN) operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry, with a market capitalization near $400.3M, listed on NASDAQ, employing roughly 27 people, carrying a beta of 5.10 to the broader market. Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. Led by Michael Lau, public since 2025-02-19.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for NNNN as of 2026-07-17; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →